Meglumine is widely used in the pharmaceutical field and market demand will continue to be released

Meglumine (N-methyl-D-glucosamine), also known as glucose methylamine, is an amino sugar derived from sorbitol. It is stable at room temperature and pressure and appears as a white crystalline powder. Meglumine is almost odorless, slightly sweet, salty, soluble in water, slightly soluble in ethanol, and almost insoluble in chloroform. Meglumine has similar permeability and ionic radius to sodium, which can improve drug solubility and bioavailability, and does not penetrate cell membranes. It is often used as a substitute for sodium in the medical field, such as co-solvent for contrast agents and surface activity. agents, co-solvents, diagnostic drugs, etc.

Meglumine has a wide range of applications and is suitable for all weakly acidic drugs with a PKa value between 2-7. Clinically, meglumine has the functions of anti-arrhythmia, cardiovascular protection, and improving myocardial metabolism. It can be used to treat coronary heart disease, cardiomyopathy, myocarditis, acute/chronic heart failure, sick sinus syndrome and other diseases. my country is a country with a large population. Against the backdrop of an aging population, the number of patients with cardiovascular disease continues to grow, which will provide broad growth space for the meglumine market.

According to the “2023-2027 Meglumine Industry In-depth Analysis and “14th Five-Year Plan” Development Plan Guidance Report released by the Industrial Research Center 》 shows that according to different product types, meglumine can be divided into diatrizoate meglumine, cholecystografin meglumine, encephalogram meglumine, etc. Globally, the meglumine market is mainly distributed in China, the United States, Europe, Southeast Asia, Japan, India and other regions. Related manufacturers include Merck, Tianma, Libang Healthcare Group, China Resources Shuanghe, Wuhan Huajiu Pharmaceutical, Chico Chemical, etc. . There are many meglumine manufacturers and the market competition is fierce.

The raw materials for the production of meglumine involve glucose, methylamine, anhydrous ethanol, hydrogen, Rae’s nickel, etc. The preparation process is in anhydrous ethanol. Glucose is first condensed with methylamine to form Schiff’s salt, and then hydrogen is used as the hydrogen source. , catalytic hydrogenation is used to synthesize meglumine under the conditions of Ley’s nickel as catalyst. However, the refining yield of this process is low and the process is cumbersome. With the upgrade of market demand, the preparation process of meglumine needs to be further optimized.

On December 19, 2022, the National Pharmacopoeia Commission successively issued 15 standards for pharmaceutical excipients, including meglumine, to solicit opinions from all walks of life. The publicity period was 3 months from the date of release. With the gradual formulation of this standard, the standards for meglumine pharmaceutical excipients will be more rational, standardized and scientific, which will benefit the development of the meglumine market.

Industry analysts said that meglumine is a chemical raw material that is widely used in the pharmaceutical field and has many downstream pharmaceutical products. As the aging of the population accelerates, the demand for meglumine applications will be further released. There are many meglumine manufacturers and the market competition is fierce. In the future, as market demand upgrades and medication standards become more scientific, unqualified companies may gradually withdraw from the market.